Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:Butylparaben
go back to main search page
Accession:CHEBI:88542 term browser browse the term
Synonyms:related_synonym: 4-(Butoxycarbonyl)phenol;   4-Hydroxybenzoic acid butyl ester;   Aseptoform butyl;   Benzoic acid, 4-hydroxy-, butyl ester;   Benzoic acid, p-hydroxy-, butyl ester;   Butoben;   Butyl 4-hydroxybenzoate;   Butyl butex;   Butyl chemosept;   Butyl par asept;   Butyl paraben;   Butyl parahydroxybenzoate;   Butyl parahydroxybenzoate (JP15);   Butyl parahydroxybenzoate (TN);   Butyl parasept;   Butyl tegosept;   Butyl-p-hydroxybenzoate;   Butylparaben (NF);   Butylparaben (TN);   Butylparaben [usan];   FEMA 2203;   Formula=C11H14O3;   InChI=1S/C11H14O3/c1-2-3-8-14-11(13)9-4-6-10(12)7-5-9/h4-7,12H,2-3,8H2,1H3;   InChIKey=QFOHBWFCKVYLES-UHFFFAOYSA-N;   Lexgard b;   N-Butyl 4-hydroxybenzoate;   N-Butyl hydroxybenzoate;   N-Butyl parahydroxybenzoate;   N-Butyl-p-hydroxybenzoate;   N-Butyl-paraben;   Nipabutyl;   P-Hydroxy butyl benzoate;   P-Hydroxybenzoic acid N-butyl ester;   P-Hydroxybenzoic acid butyl ester;   P-Hydroxybenzoic butyl ester;   Parasept;   Preserval b;   SMILES=CCCCOC(C1=CC=C(C=C1)O)=O;   SPF;   Solbrol b;   Tegosept B
 alt_id: CHEBI:31329
 xref: CAS:94-26-8;   HMDB:HMDB0032575;   KEGG:D01420;   LINCS:LSM-2161
 xref_mesh: MESH:C038091
 xref: PMID:18294789


show annotations for term's descendants           Sort by:
 
Butylparaben term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aars2 alanyl-tRNA synthetase 2, mitochondrial increases expression ISO butylparaben results in increased expression of AARS2 mRNA CTD PMID:17121429 NCBI chr 9:15,484,639...15,496,116
Ensembl chr 9:15,297,531...15,496,090
JBrowse link
G Abat 4-aminobutyrate aminotransferase multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ABAT mRNA CTD PMID:25607892 NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835
JBrowse link
G Acan aggrecan decreases expression ISO butylparaben results in decreased expression of ACAN mRNA CTD PMID:28527915 NCBI chr 1:132,981,034...133,044,416
Ensembl chr 1:132,981,582...133,043,627
JBrowse link
G Acsl6 acyl-CoA synthetase long-chain family member 6 increases expression ISO butylparaben results in increased expression of ACSL6 mRNA CTD PMID:17121429 NCBI chr10:38,439,914...38,501,182
Ensembl chr10:38,440,080...38,498,757
JBrowse link
G Actn1 actinin, alpha 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ACTN1 mRNA CTD PMID:25607892 NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251
JBrowse link
G Adam17 ADAM metallopeptidase domain 17 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ADAM17 mRNA CTD PMID:25607892 NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions
increases expression
ISO butylparaben promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]
butylparaben results in increased expression of ADIPOQ mRNA
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [butylparaben results in increased expression of ADIPOQ mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [butylparaben results in increased expression of ADIPOQ mRNA]; butylparaben promotes the reaction [Dexamethasone results in increased expression of ADIPOQ mRNA]; Mifepristone inhibits the reaction [butylparaben results in increased expression of ADIPOQ mRNA]
CTD PMID:22956630 PMID:31016361 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
JBrowse link
G Adm adrenomedullin decreases expression ISO butylparaben results in decreased expression of ADM mRNA CTD PMID:17121429 NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
JBrowse link
G Alpl alkaline phosphatase, biomineralization associated decreases expression
multiple interactions
ISO butylparaben results in decreased expression of ALPL mRNA
NR3C1 protein promotes the reaction [butylparaben results in decreased expression of ALPL mRNA]; PPARG protein promotes the reaction [butylparaben results in decreased expression of ALPL mRNA]
CTD PMID:28527915 NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
JBrowse link
G Ar androgen receptor affects binding
affects expression
decreases expression
EXP butylparaben binds to AR protein
butylparaben affects the expression of AR protein
butylparaben results in decreased expression of AR mRNA; butylparaben results in decreased expression of AR protein
CTD PMID:20371976 PMID:26888303 PMID:27444704 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Arhgap9 Rho GTPase activating protein 9 increases expression ISO butylparaben results in increased expression of ARHGAP9 mRNA CTD PMID:17121429 NCBI chr 7:63,148,573...63,157,025
Ensembl chr 7:63,148,900...63,157,524
JBrowse link
G Atf6 activating transcription factor 6 increases expression ISO butylparaben results in increased expression of ATF6 protein CTD PMID:29319206 NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
JBrowse link
G Atm ATM serine/threonine kinase affects expression ISO butylparaben affects the expression of ATM mRNA CTD PMID:24481588 NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
JBrowse link
G Atp5mg ATP synthase membrane subunit g increases expression ISO butylparaben results in increased expression of ATP5L mRNA CTD PMID:17121429 NCBI chr 8:45,226,750...45,233,582
Ensembl chr 8:45,225,686...45,233,559
JBrowse link
G Atr ATR serine/threonine kinase increases expression ISO butylparaben results in increased expression of ATR mRNA CTD PMID:24481588 NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
JBrowse link
G Bcl2l1 Bcl2-like 1 increases expression ISO butylparaben results in increased expression of BCL2L1 mRNA; butylparaben results in increased expression of BCL2L1 protein CTD PMID:24481588 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of BDNF mRNA CTD PMID:25607892 NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
JBrowse link
G Bglap bone gamma-carboxyglutamate protein decreases expression ISO butylparaben results in decreased expression of BGLAP mRNA CTD PMID:28527915 NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
JBrowse link
G Bsn bassoon (presynaptic cytomatrix protein) multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of BSN mRNA CTD PMID:25607892 NCBI chr 8:108,784,849...108,875,819
Ensembl chr 8:108,788,542...108,875,819
JBrowse link
G Cacna1a calcium voltage-gated channel subunit alpha1 A multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1A mRNA CTD PMID:25607892 NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225
JBrowse link
G Cacna1c calcium voltage-gated channel subunit alpha1 C multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA1C mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1C mRNA CTD PMID:25607892 NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648
JBrowse link
G Cacna1d calcium voltage-gated channel subunit alpha1 D multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA1D mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1D mRNA CTD PMID:25607892 NCBI chr16:5,227,157...5,521,163
Ensembl chr16:5,228,306...5,668,215
JBrowse link
G Cacna1e calcium voltage-gated channel subunit alpha1 E multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1E mRNA CTD PMID:25607892 NCBI chr13:66,574,659...67,063,443
Ensembl chr13:66,581,920...66,894,450
JBrowse link
G Cacna1f calcium voltage-gated channel subunit alpha1 F multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1F mRNA CTD PMID:25607892 NCBI chr  X:14,868,096...14,896,413
Ensembl chr  X:14,868,024...14,896,413
JBrowse link
G Cacna1g calcium voltage-gated channel subunit alpha1 G multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNA1G mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1G mRNA CTD PMID:25607892 NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752
JBrowse link
G Cacna1h calcium voltage-gated channel subunit alpha1 H multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1H mRNA CTD PMID:25607892 NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376
JBrowse link
G Cacna1i calcium voltage-gated channel subunit alpha1 I multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNA1I mRNA CTD PMID:25607892 NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688
JBrowse link
G Cacna2d1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA2D1 mRNA CTD PMID:25607892 NCBI chr 4:18,950,611...19,374,969
Ensembl chr 4:18,951,002...19,374,969
JBrowse link
G Cacna2d2 calcium voltage-gated channel auxiliary subunit alpha2delta 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D2 mRNA CTD PMID:25607892 NCBI chr 8:108,072,208...108,203,516
Ensembl chr 8:108,072,454...108,203,173
JBrowse link
G Cacna2d3 calcium voltage-gated channel auxiliary subunit alpha2delta 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA2D3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D3 mRNA CTD PMID:25607892 NCBI chr16:4,098,439...4,912,498
Ensembl chr16:4,098,445...4,912,351
JBrowse link
G Cacnb1 calcium voltage-gated channel auxiliary subunit beta 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB1 mRNA CTD PMID:25607892 NCBI chr10:82,998,182...83,018,838
Ensembl chr10:82,998,182...83,018,694
JBrowse link
G Cacnb2 calcium voltage-gated channel auxiliary subunit beta 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB2 mRNA CTD PMID:25607892 NCBI chr17:77,564,630...77,910,000
Ensembl chr17:77,564,460...77,909,106
JBrowse link
G Cacnb3 calcium voltage-gated channel auxiliary subunit beta 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNB3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB3 mRNA CTD PMID:25607892 NCBI chr 7:129,784,799...129,797,074
Ensembl chr 7:129,783,674...129,797,074
JBrowse link
G Cacng2 calcium voltage-gated channel auxiliary subunit gamma 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNG2 mRNA CTD PMID:25607892 NCBI chr 7:109,572,838...109,698,516
Ensembl chr 7:109,574,459...109,697,227
JBrowse link
G Cacng5 calcium voltage-gated channel auxiliary subunit gamma 5 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG5 mRNA CTD PMID:25607892 NCBI chr10:92,827,441...92,869,632
Ensembl chr10:92,829,196...92,869,614
JBrowse link
G Cacng6 calcium voltage-gated channel auxiliary subunit gamma 6 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNG6 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG6 mRNA CTD PMID:25607892 NCBI chr 1:65,732,910...65,747,377
Ensembl chr 1:65,732,632...65,747,341
JBrowse link
G Cacng8 calcium voltage-gated channel auxiliary subunit gamma 8 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG8 mRNA CTD PMID:25607892 NCBI chr 1:65,755,334...65,775,567
Ensembl chr 1:65,755,334...65,779,089
JBrowse link
G Calb2 calbindin 2 increases expression ISO butylparaben results in increased expression of CALB2 mRNA CTD PMID:17121429 NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438
JBrowse link
G Camk2b calcium/calmodulin-dependent protein kinase II beta multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CAMK2B mRNA CTD PMID:25607892 NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
JBrowse link
G Cask calcium/calmodulin dependent serine protein kinase multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CASK mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CASK mRNA CTD PMID:25607892 NCBI chr  X:8,899,500...9,243,014
Ensembl chr  X:8,899,833...9,238,694
JBrowse link
G Casp8 caspase 8 increases expression ISO butylparaben results in increased expression of CASP8 protein CTD PMID:24481588 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Cat catalase decreases activity
multiple interactions
EXP butylparaben results in decreased activity of CAT protein
butylparaben inhibits the reaction [Triclosan results in increased activity of CAT protein]
CTD PMID:29350491 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ccna1 cyclin A1 increases expression ISO butylparaben results in increased expression of CCNA1 mRNA CTD PMID:24481588 NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157
JBrowse link
G Ccna2 cyclin A2 increases expression ISO butylparaben results in increased expression of CCNA2 mRNA CTD PMID:24481588 NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
JBrowse link
G Ccnb2 cyclin B2 increases expression ISO butylparaben results in increased expression of CCNB2 mRNA CTD PMID:24481588 NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
JBrowse link
G Ccnd1 cyclin D1 increases expression ISO butylparaben results in increased expression of CCND1 mRNA CTD PMID:23524099 PMID:24481588 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Ccnd3 cyclin D3 affects expression
decreases expression
ISO butylparaben affects the expression of CCND3 mRNA
butylparaben results in decreased expression of CCND3 mRNA
CTD PMID:24481588 NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
JBrowse link
G Ccne1 cyclin E1 affects expression ISO butylparaben affects the expression of CCNE1 mRNA CTD PMID:24481588 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
JBrowse link
G Ccne2 cyclin E2 increases expression ISO butylparaben results in increased expression of CCNE2 mRNA CTD PMID:24481588 NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
JBrowse link
G Cd44 CD44 molecule (Indian blood group) multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CD44 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CD44 mRNA CTD PMID:25607892 NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
JBrowse link
G Cdc25a cell division cycle 25A increases expression ISO butylparaben results in increased expression of CDC25A mRNA CTD PMID:24481588 NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701
JBrowse link
G Cdk2 cyclin dependent kinase 2 increases expression ISO butylparaben results in increased expression of CDK2 mRNA CTD PMID:24481588 NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
JBrowse link
G Cdk4 cyclin-dependent kinase 4 increases expression ISO butylparaben results in increased expression of CDK4 mRNA CTD PMID:24481588 NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
JBrowse link
G Cdk6 cyclin-dependent kinase 6 affects expression ISO butylparaben affects the expression of CDK6 mRNA CTD PMID:24481588 NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A decreases expression ISO butylparaben results in decreased expression of CDKN1A mRNA; butylparaben results in decreased expression of CDKN1A protein CTD PMID:24481588 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions
increases expression
ISO 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [butylparaben results in increased expression of CEBPA mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [butylparaben results in increased expression of CEBPA mRNA]; butylparaben promotes the reaction [Dexamethasone results in increased expression of CEBPA mRNA]; Mifepristone inhibits the reaction [butylparaben results in increased expression of CEBPA mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of CEBPA mRNA]; Rimonabant inhibits the reaction [butylparaben results in increased expression of CEBPA mRNA] CTD PMID:22956630 PMID:27659731 PMID:28527915 NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
JBrowse link
G Celf5 CUGBP, Elav-like family member 5 increases expression ISO butylparaben results in increased expression of CELF5 mRNA CTD PMID:17121429 NCBI chr 7:8,225,787...8,250,322
Ensembl chr 7:8,225,825...8,250,322
JBrowse link
G Chrdl1 chordin-like 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CHRDL1 mRNA CTD PMID:25607892 NCBI chr  X:106,889,125...106,992,937
Ensembl chr  X:106,889,125...106,992,921
JBrowse link
G Chst1 carbohydrate sulfotransferase 1 increases expression ISO butylparaben results in increased expression of CHST1 mRNA CTD PMID:17121429 NCBI chr 3:78,552,059...78,574,736
Ensembl chr 3:78,548,525...78,574,883
JBrowse link
G Cntn3 contactin 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN3 mRNA CTD PMID:25607892 NCBI chr 4:134,841,268...135,214,460
Ensembl chr 4:134,842,266...135,125,613
JBrowse link
G Cntn4 contactin 4 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN4 mRNA CTD PMID:25607892 NCBI chr 4:138,624,584...139,622,499
Ensembl chr 4:139,099,152...139,621,090
JBrowse link
G Col10a1 collagen type X alpha 1 chain decreases expression ISO butylparaben results in decreased expression of COL10A1 mRNA CTD PMID:28527915 NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
JBrowse link
G Col2a1 collagen type II alpha 1 chain decreases expression ISO butylparaben results in decreased expression of COL2A1 mRNA CTD PMID:28527915 NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
JBrowse link
G Col8a1 collagen type VIII alpha 1 chain increases expression ISO butylparaben results in increased expression of COL8A1 mRNA CTD PMID:17121429 NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424
JBrowse link
G Cops2 COP9 signalosome subunit 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of COPS2 mRNA CTD PMID:25607892 NCBI chr 3:113,084,174...113,110,090
Ensembl chr 3:113,084,176...113,109,947
JBrowse link
G Cyba cytochrome b-245 alpha chain increases expression ISO butylparaben results in increased expression of CYBA mRNA CTD PMID:17121429 NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
JBrowse link
G Cycs cytochrome c, somatic increases expression ISO butylparaben results in increased expression of CYCS protein CTD PMID:29319206 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 decreases expression EXP butylparaben results in decreased expression of CYP11A1 mRNA; butylparaben results in decreased expression of CYP11A1 protein CTD PMID:26888303 NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
JBrowse link
G Cyp11b1 cytochrome P450, family 11, subfamily b, polypeptide 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CYP11B1 mRNA CTD PMID:25607892 NCBI chr 7:106,772,597...106,780,536
Ensembl chr 7:106,718,274...106,779,278
JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CYP17A1 mRNA CTD PMID:25607892 NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 decreases expression
increases expression
increases activity
multiple interactions
affects expression
EXP
ISO
butylparaben results in decreased expression of CYP19A1 mRNA
butylparaben results in increased expression of CYP19A1 mRNA
butylparaben results in decreased expression of CYP19A1 mRNA; butylparaben results in decreased expression of CYP19A1 protein
butylparaben results in increased activity of CYP19A1 protein
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CYP19A1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CYP19A1 mRNA
butylparaben affects the expression of CYP19A1 protein
CTD PMID:23744433 PMID:25607892 PMID:26888303 PMID:27122241 PMID:30817981 NCBI chr 8:54,553,165...54,580,758
Ensembl chr 8:54,553,165...54,580,758
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions
decreases activity
ISO
EXP
[butylparaben co-treated with triclocarban] results in increased expression of CYP1A1 mRNA
butylparaben results in decreased activity of CYP1A1 protein
CTD PMID:23524099 PMID:27432241 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases activity EXP butylparaben results in decreased activity of CYP1A2 protein CTD PMID:27432241 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression
multiple interactions
ISO butylparaben results in increased expression of CYP1B1 mRNA
butylparaben promotes the reaction [bisphenol A results in increased expression of CYP1B1 mRNA]
CTD PMID:23524099 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 decreases activity EXP butylparaben results in decreased activity of CYP2B1 protein CTD PMID:27432241 NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 decreases activity EXP butylparaben results in decreased activity of CYP2C11 protein CTD PMID:27432241 NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 decreases activity EXP butylparaben results in decreased activity of CYP2E1 protein CTD PMID:27432241 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
JBrowse link
G Cyp3a62 cytochrome P450, family 3, subfamily a, polypeptide 62 decreases activity EXP butylparaben results in decreased activity of CYP3A62 protein CTD PMID:27432241 NCBI chr12:16,397,998...16,433,833
Ensembl chr12:16,397,998...16,433,833
JBrowse link
G Dcc DCC netrin 1 receptor multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DCC mRNA CTD PMID:25607892 NCBI chr18:64,868,987...65,972,783
Ensembl chr18:64,873,898...65,972,740
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression ISO butylparaben results in increased expression of DDIT3 protein CTD PMID:29319206 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein increases expression ISO butylparaben results in increased expression of DIABLO mRNA CTD PMID:24481588 NCBI chr12:33,055,784...33,070,400
Ensembl chr12:33,055,263...33,070,387
JBrowse link
G Dio1 iodothyronine deiodinase 1 affects expression
decreases activity
EXP butylparaben affects the expression of DIO1 mRNA
butylparaben results in decreased activity of DIO1 protein
CTD PMID:32798586 NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
JBrowse link
G Dlg1 discs large MAGUK scaffold protein 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLG1 mRNA CTD PMID:25607892 NCBI chr11:68,911,883...69,103,230
Ensembl chr11:68,911,883...69,102,689
JBrowse link
G Dlg4 discs large MAGUK scaffold protein 4 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DLG4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLG4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of DLG4 mRNA CTD PMID:25607892 NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153
JBrowse link
G Dlgap3 DLG associated protein 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of DLGAP3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLGAP3 mRNA CTD PMID:25607892 NCBI chr 5:139,491,972...139,562,625
Ensembl chr 5:139,492,947...139,562,625
JBrowse link
G Dnmt3a DNA methyltransferase 3 alpha multiple interactions
increases expression
EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DNMT3A mRNA
butylparaben results in increased expression of DNMT3A mRNA
CTD PMID:25607892 PMID:26888303 NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
JBrowse link
G Dnmt3b DNA methyltransferase 3 beta increases expression EXP butylparaben results in increased expression of DNMT3B mRNA CTD PMID:26888303 NCBI chr 3:142,130,592...142,169,124
Ensembl chr 3:142,130,592...142,169,124
JBrowse link
G Dpp6 dipeptidyl peptidase like 6 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of DPP6 mRNA CTD PMID:25607892 NCBI chr 4:7,589,386...8,508,666
Ensembl chr 4:7,591,009...8,508,532
JBrowse link
G E2f1 E2F transcription factor 1 affects expression ISO butylparaben affects the expression of E2F1 mRNA CTD PMID:24481588 NCBI chr 3:143,064,535...143,075,362 JBrowse link
G E2f3 E2F transcription factor 3 affects expression ISO butylparaben affects the expression of E2F3 mRNA CTD PMID:24481588 NCBI chr17:34,601,756...34,679,139
Ensembl chr17:34,601,830...34,676,253
JBrowse link
G Efna4 ephrin A4 increases expression ISO butylparaben results in increased expression of EFNA4 mRNA CTD PMID:17121429 NCBI chr 2:174,748,729...174,752,979
Ensembl chr 2:174,748,724...174,752,979
JBrowse link
G Egf epidermal growth factor multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of EGF mRNA CTD PMID:25607892 NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
JBrowse link
G Elp6 elongator acetyltransferase complex subunit 6 increases expression ISO butylparaben results in increased expression of ELP6 mRNA CTD PMID:17121429 NCBI chr 8:110,280,059...110,295,070
Ensembl chr 8:110,279,979...110,295,067
JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA CTD PMID:25607892 NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
JBrowse link
G Erbb3 erb-b2 receptor tyrosine kinase 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB3 mRNA CTD PMID:25607892 NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
JBrowse link
G Erbb4 erb-b2 receptor tyrosine kinase 4 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of ERBB4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of ERBB4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB4 mRNA CTD PMID:25607892 NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
JBrowse link
G Ercc2 ERCC excision repair 2, TFIIH core complex helicase subunit increases expression ISO butylparaben results in increased expression of ERCC2 mRNA CTD PMID:17121429 NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102
JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 increases expression ISO butylparaben results in increased expression of ERN1 protein CTD PMID:29319206 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
JBrowse link
G Esr1 estrogen receptor 1 affects binding
increases activity
decreases expression
multiple interactions
decreases activity
increases expression
decreases methylation
ISO
EXP
butylparaben binds to ESR1 protein; butylparaben metabolite binds to ESR1 protein
butylparaben results in increased activity of ESR1 protein
butylparaben results in decreased expression of ESR1 mRNA; butylparaben results in decreased expression of ESR1 protein
butylparaben inhibits the reaction [Estradiol binds to ESR1 protein]; Fulvestrant inhibits the reaction [butylparaben results in decreased expression of ESR1 mRNA]; Fulvestrant inhibits the reaction [butylparaben results in decreased expression of ESR1 protein]
butylparaben results in decreased activity of ESR1 protein
butylparaben results in increased expression of ESR1 mRNA; butylparaben results in increased expression of ESR1 protein
[butylparaben co-treated with NRG1 protein] promotes the reaction [ESR1 protein binds to MYC enhancer]; butylparaben binds to and results in increased activity of ESR1 protein; Fulvestrant inhibits the reaction [butylparaben results in increased activity of ESR1 protein]
butylparaben results in decreased methylation of ESR1 promoter
CTD PMID:11193391 PMID:15204698 PMID:19063592 PMID:19654335 PMID:20074635 More... NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Esr2 estrogen receptor 2 affects binding
multiple interactions
increases expression
decreases expression
EXP
ISO
butylparaben binds to ESR2 protein
butylparaben binds to and results in increased activity of ESR2 protein
butylparaben results in increased expression of ESR2 mRNA
butylparaben results in decreased expression of ESR2 mRNA
butylparaben results in increased expression of ESR2 mRNA; butylparaben results in increased expression of ESR2 protein
CTD PMID:11193391 PMID:18648085 PMID:20132880 PMID:23567241 PMID:25128701 More... NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
JBrowse link
G Esrrg estrogen-related receptor gamma multiple interactions ISO butylparaben inhibits the reaction [afimoxifene inhibits the reaction [ESRRG protein binds to NCOA2 protein]] CTD PMID:23583298 NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397
JBrowse link
G Faah fatty acid amide hydrolase decreases activity ISO
EXP
butylparaben results in decreased activity of FAAH protein CTD PMID:27659731 NCBI chr 5:129,479,774...129,499,018 JBrowse link
G Faahl fatty-acid amide hydrolase-like decreases activity ISO butylparaben results in decreased activity of FAAH protein CTD PMID:27659731
G Fabp4 fatty acid binding protein 4 multiple interactions
increases expression
ISO butylparaben promotes the reaction [Dexamethasone results in increased expression of FABP4 mRNA]; NR3C1 protein promotes the reaction [butylparaben results in increased expression of FABP4 mRNA]; PPARG mutant form inhibits the reaction [butylparaben results in increased expression of FABP4 mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of FABP4 mRNA] CTD PMID:22956630 PMID:24155963 PMID:27659731 PMID:28527915 NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
JBrowse link
G Fasn fatty acid synthase increases expression
multiple interactions
ISO butylparaben results in increased expression of FASN mRNA
butylparaben promotes the reaction [Dexamethasone results in increased expression of FASN mRNA]
CTD PMID:22956630 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
JBrowse link
G Fgfr1 Fibroblast growth factor receptor 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of FGFR1 mRNA CTD PMID:25607892 NCBI chr16:66,492,445...66,546,731
Ensembl chr16:66,494,042...66,547,350
JBrowse link
G Fgfr2 fibroblast growth factor receptor 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of FGFR2 mRNA CTD PMID:25607892 NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
JBrowse link
G Fshb follicle stimulating hormone subunit beta decreases secretion
decreases expression
EXP butylparaben results in decreased secretion of FSHB protein
butylparaben results in decreased expression of FSHB protein
CTD PMID:27444704 PMID:29350491 NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
JBrowse link
G Fus FUS RNA binding protein increases expression ISO butylparaben results in increased expression of FUS mRNA CTD PMID:17121429 NCBI chr 1:182,576,479...182,590,417
Ensembl chr 1:182,576,545...182,590,414
JBrowse link
G Fyn FYN proto-oncogene, Src family tyrosine kinase multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of FYN mRNA CTD PMID:25607892 NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
JBrowse link
G Gabra4 gamma-aminobutyric acid type A receptor subunit alpha 4 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GABRA4 mRNA CTD PMID:25607892 NCBI chr14:36,590,782...36,667,724
Ensembl chr14:36,590,782...36,665,844
JBrowse link
G Gabrb1 gamma-aminobutyric acid type A receptor subunit beta1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GABRB1 mRNA CTD PMID:25607892 NCBI chr14:36,068,725...36,548,946
Ensembl chr14:36,080,393...36,548,948
JBrowse link
G Gls glutaminase multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GLS mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GLS mRNA CTD PMID:25607892 NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
JBrowse link
G Gper1 G protein-coupled estrogen receptor 1 increases expression ISO butylparaben results in increased expression of GPER1 mRNA; butylparaben results in increased expression of GPER1 protein CTD PMID:17121429 PMID:26253279 NCBI chr12:15,217,217...15,222,679
Ensembl chr12:15,217,442...15,221,889
JBrowse link
G Greb1 growth regulating estrogen receptor binding 1 multiple interactions
increases expression
ISO Fulvestrant inhibits the reaction [butylparaben metabolite results in increased expression of GREB1 mRNA]; Fulvestrant inhibits the reaction [butylparaben results in increased expression of GREB1 mRNA]
butylparaben metabolite results in increased expression of GREB1 mRNA; butylparaben results in increased expression of GREB1 mRNA
CTD PMID:17121429 PMID:29945225 NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633
JBrowse link
G Gria2 glutamate ionotropic receptor AMPA type subunit 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA2 mRNA CTD PMID:25607892 NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
JBrowse link
G Gria4 glutamate ionotropic receptor AMPA type subunit 4 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIA4 mRNA CTD PMID:25607892 NCBI chr 8:1,562,118...2,035,035
Ensembl chr 8:1,562,119...2,034,979
JBrowse link
G Grik2 glutamate ionotropic receptor kainate type subunit 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIK2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIK2 mRNA CTD PMID:25607892 NCBI chr20:52,135,325...52,833,061
Ensembl chr20:52,133,851...52,838,375
JBrowse link
G Grik4 glutamate ionotropic receptor kainate type subunit 4 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIK4 mRNA CTD PMID:25607892 NCBI chr 8:42,903,043...43,331,990
Ensembl chr 8:42,905,056...43,193,751
JBrowse link
G Grik5 glutamate ionotropic receptor kainate type subunit 5 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIK5 mRNA CTD PMID:25607892 NCBI chr 1:80,605,878...80,667,896
Ensembl chr 1:80,605,892...80,667,125
JBrowse link
G Grin1 glutamate ionotropic receptor NMDA type subunit 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of GRIN1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIN1 mRNA CTD PMID:25607892 NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
JBrowse link
G Grin2b glutamate ionotropic receptor NMDA type subunit 2B multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN2B mRNA CTD PMID:25607892 NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
JBrowse link
G Grin2c glutamate ionotropic receptor NMDA type subunit 2C multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN2C mRNA CTD PMID:25607892 NCBI chr10:100,488,430...100,507,083
Ensembl chr10:100,488,431...100,506,427
JBrowse link
G Grin2d glutamate ionotropic receptor NMDA type subunit 2D multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIN2D mRNA CTD PMID:25607892 NCBI chr 1:96,306,871...96,346,994
Ensembl chr 1:96,308,365...96,344,793
JBrowse link
G Grin3a glutamate ionotropic receptor NMDA type subunit 3A multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN3A mRNA CTD PMID:25607892 NCBI chr 5:64,006,847...64,206,408
Ensembl chr 5:64,009,980...64,206,085
JBrowse link
G Grip1 glutamate receptor interacting protein 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIP1 mRNA CTD PMID:25607892 NCBI chr 7:54,934,856...55,592,274
Ensembl chr 7:54,934,250...55,592,273
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta decreases phosphorylation ISO butylparaben results in decreased phosphorylation of GSK3B protein CTD PMID:29319206 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
JBrowse link
G Hes6 hes family bHLH transcription factor 6 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of HES6 mRNA CTD PMID:25607892 NCBI chr 9:92,001,838...92,003,580
Ensembl chr 9:92,001,841...92,003,559
JBrowse link
G Hexb hexosaminidase subunit beta multiple interactions EXP zinc chloride inhibits the reaction [butylparaben results in increased secretion of HEXB protein] CTD PMID:15272608 NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223
JBrowse link
G Hps6 HPS6, biogenesis of lysosomal organelles complex 2 subunit 3 increases expression ISO butylparaben results in increased expression of HPS6 mRNA CTD PMID:17121429 NCBI chr 1:244,853,256...244,855,865
Ensembl chr 1:244,853,194...244,855,883
JBrowse link
G Hr HR, lysine demethylase and nuclear receptor corepressor multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of HR mRNA CTD PMID:25607892 NCBI chr15:45,626,835...45,646,313
Ensembl chr15:45,626,835...45,646,313
JBrowse link
G Hsd17b10 hydroxysteroid (17-beta) dehydrogenase 10 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of HSD17B10 mRNA CTD PMID:25607892 NCBI chr  X:21,089,152...21,091,597
Ensembl chr  X:21,089,122...21,109,488
JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of HSD17B8 mRNA CTD PMID:25607892 NCBI chr20:4,826,725...4,828,742
Ensembl chr20:4,822,026...4,828,742
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 increases expression ISO butylparaben results in increased expression of HSPA5 protein CTD PMID:29319206 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
JBrowse link
G Hspb8 heat shock protein family B (small) member 8 increases expression ISO butylparaben results in increased expression of HSPB8 mRNA CTD PMID:23524099 NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185
JBrowse link
G Igdcc3 immunoglobulin superfamily, DCC subclass, member 3 increases expression ISO butylparaben results in increased expression of IGDCC3 mRNA CTD PMID:17121429 NCBI chr 8:65,661,165...65,707,961
Ensembl chr 8:65,661,196...65,707,959
JBrowse link
G Igf1r insulin-like growth factor 1 receptor multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of IGF1R mRNA CTD PMID:25607892 NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
JBrowse link
G Igf2r insulin-like growth factor 2 receptor multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of IGF2R mRNA CTD PMID:25607892 NCBI chr 1:47,979,109...48,067,501
Ensembl chr 1:47,979,109...48,067,501
JBrowse link
G Il17rb interleukin 17 receptor B increases expression ISO butylparaben results in increased expression of IL17RB mRNA CTD PMID:17121429 NCBI chr16:5,180,431...5,194,125
Ensembl chr16:5,180,432...5,194,125
JBrowse link
G Il1rapl1 interleukin 1 receptor accessory protein-like 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of IL1RAPL1 mRNA CTD PMID:25607892 NCBI chr  X:51,371,969...52,876,726
Ensembl chr  X:51,378,215...52,876,772
JBrowse link
G Incenp inner centromere protein increases expression ISO butylparaben results in increased expression of INCENP mRNA CTD PMID:17121429 NCBI chr 1:206,520,655...206,550,575
Ensembl chr 1:206,523,380...206,553,265
JBrowse link
G Ins2 insulin 2 multiple interactions ISO butylparaben promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased secretion of TNFRSF11B protein]; butylparaben promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein] CTD PMID:31016361 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
JBrowse link
G Jag1 jagged canonical Notch ligand 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of JAG1 mRNA CTD PMID:25607892 NCBI chr 3:124,406,794...124,442,220
Ensembl chr 3:124,406,794...124,442,209
JBrowse link
G Kcnc1 potassium voltage-gated channel subfamily C member 1 increases expression ISO butylparaben results in increased expression of KCNC1 mRNA CTD PMID:17121429 NCBI chr 1:96,902,953...96,944,744
Ensembl chr 1:96,902,953...96,944,744
JBrowse link
G Kcnf1 potassium voltage-gated channel modifier subfamily F member 1 increases expression ISO butylparaben results in increased expression of KCNF1 mRNA CTD PMID:17121429 NCBI chr 6:39,962,301...39,964,979
Ensembl chr 6:39,962,307...39,964,979
JBrowse link
G Krt8 keratin 8 increases expression ISO butylparaben results in increased expression of KRT8 mRNA CTD PMID:17121429 NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
JBrowse link
G Krt82 keratin 82 increases expression ISO butylparaben results in increased expression of KRT82 mRNA CTD PMID:17121429 NCBI chr 7:132,665,506...132,675,362
Ensembl chr 7:132,665,292...132,675,489
JBrowse link
G Lef1 lymphoid enhancer binding factor 1 increases expression ISO butylparaben results in increased expression of LEF1 mRNA CTD PMID:17121429 NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
JBrowse link
G Lep leptin decreases expression
increases expression
ISO butylparaben results in decreased expression of LEP mRNA
butylparaben results in increased expression of LEP mRNA
CTD PMID:22956630 NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions
decreases secretion
decreases expression
EXP butylparaben promotes the reaction [Triclosan results in decreased secretion of LHB protein]; Triclosan promotes the reaction [butylparaben results in decreased secretion of LHB protein]
butylparaben results in decreased expression of LHB protein
CTD PMID:27444704 PMID:29350491 NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972
JBrowse link
G Lin7a lin-7 homolog A, crumbs cell polarity complex component multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of LIN7A mRNA CTD PMID:25607892 NCBI chr 7:42,586,704...42,742,609
Ensembl chr 7:42,586,719...42,730,550
JBrowse link
G Lmod1 leiomodin 1 increases expression ISO butylparaben results in increased expression of LMOD1 mRNA CTD PMID:17121429 NCBI chr13:46,754,048...46,796,186
Ensembl chr13:46,754,033...46,794,900
JBrowse link
G Lpin1 lipin 1 multiple interactions
increases expression
ISO [Dexamethasone co-treated with butylparaben] results in increased expression of LPIN1 mRNA; NR3C1 mutant form inhibits the reaction [butylparaben results in increased expression of LPIN1 mRNA] CTD PMID:22956630 NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097
JBrowse link
G Lrrc29 leucine rich repeat containing 29 increases expression ISO butylparaben results in increased expression of LRRC29 mRNA CTD PMID:17121429 NCBI chr19:33,181,713...33,203,583
Ensembl chr19:33,188,352...33,203,545
JBrowse link
G Magi2 membrane associated guanylate kinase, WW and PDZ domain containing 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of MAGI2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MAGI2 mRNA CTD PMID:25607892 NCBI chr 4:14,388,322...15,870,036
Ensembl chr 4:14,386,399...15,870,240
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation ISO butylparaben results in increased phosphorylation of MAPK1 protein CTD PMID:26253279 PMID:29319206 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases phosphorylation ISO butylparaben results in increased phosphorylation of MAPK3 protein CTD PMID:26253279 PMID:29319206 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Masp1 MBL associated serine protease 1 increases expression ISO butylparaben results in increased expression of MASP1 mRNA CTD PMID:17121429 NCBI chr11:77,334,794...77,405,271
Ensembl chr11:77,334,859...77,402,974
JBrowse link
G Mdga2 MAM domain containing glycosylphosphatidylinositol anchor 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of MDGA2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MDGA2 mRNA CTD PMID:25607892 NCBI chr 6:84,746,422...85,608,640
Ensembl chr 6:84,761,941...85,608,126
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MET mRNA CTD PMID:25607892 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
JBrowse link
G Mmp3 matrix metallopeptidase 3 multiple interactions EXP [enzacamene co-treated with octylmethoxycinnamate co-treated with bisphenol A co-treated with butylparaben] results in increased expression of MMP3 mRNA CTD PMID:25305543 NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases expression
multiple interactions
ISO butylparaben results in increased expression of MYC mRNA
[butylparaben co-treated with NRG1 protein] promotes the reaction [ESR1 protein binds to MYC enhancer]; [NRG1 protein co-treated with butylparaben] results in increased expression of MYC protein; butylparaben promotes the reaction [NRG1 protein results in increased expression of MYC mRNA]; NRG1 protein promotes the reaction [butylparaben results in increased expression of MYC mRNA]
CTD PMID:26502914 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Ncoa2 nuclear receptor coactivator 2 multiple interactions ISO butylparaben inhibits the reaction [afimoxifene inhibits the reaction [ESRRG protein binds to NCOA2 protein]] CTD PMID:23583298 NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
JBrowse link
G Nf1 neurofibromin 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NF1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NF1 mRNA CTD PMID:25607892 NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658
JBrowse link
G Nlgn1 neuroligin 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NLGN1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NLGN1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NLGN1 mRNA CTD PMID:25607892 NCBI chr 2:108,256,236...109,181,530
Ensembl chr 2:108,257,824...109,002,464
JBrowse link
G Notch2 notch receptor 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NOTCH2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NOTCH2 mRNA CTD PMID:25607892 NCBI chr 2:185,610,594...185,744,088
Ensembl chr 2:185,610,589...185,744,088
JBrowse link
G Notch4 notch receptor 4 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NOTCH4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NOTCH4 mRNA CTD PMID:25607892 NCBI chr20:4,160,362...4,184,466
Ensembl chr20:4,160,445...4,184,465
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases expression EXP
ISO
butylparaben results in increased expression of NR1I2 mRNA CTD PMID:31472229 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases expression EXP butylparaben results in increased expression of NR1I3 mRNA CTD PMID:31472229 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 multiple interactions
increases activity
increases response to substance
ISO NR3C1 mutant form inhibits the reaction [butylparaben results in increased expression of LPIN1 mRNA]; NR3C1 protein promotes the reaction [butylparaben results in decreased expression of ALPL mRNA]; NR3C1 protein promotes the reaction [butylparaben results in decreased expression of SPP1 mRNA]; NR3C1 protein promotes the reaction [butylparaben results in increased expression of FABP4 mRNA]; NR3C1 protein promotes the reaction [butylparaben results in increased expression of PLIN1 mRNA]
butylparaben results in increased activity of NR3C1 protein
[butylparaben co-treated with propylparaben] results in increased activity of NR3C1 protein; [Diethylhexyl Phthalate co-treated with butylparaben co-treated with propylparaben] results in increased activity of NR3C1 protein; [Diethylhexyl Phthalate co-treated with butylparaben co-treated with tetramethrin co-treated with propylparaben] results in increased activity of NR3C1 protein; [Diethylhexyl Phthalate co-treated with butylparaben co-treated with tetramethrin] results in increased activity of NR3C1 protein; [Diethylhexyl Phthalate co-treated with butylparaben] results in increased activity of NR3C1 protein
NR3C1 protein results in increased susceptibility to butylparaben
CTD PMID:22956630 PMID:25448277 PMID:28527915 NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
JBrowse link
G Nr3c2 nuclear receptor subfamily 3, group C, member 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NR3C2 mRNA CTD PMID:25607892 NCBI chr19:30,715,648...31,059,885
Ensembl chr19:30,715,648...31,059,885
JBrowse link
G Nr5a1 nuclear receptor subfamily 5, group A, member 1 decreases expression EXP butylparaben results in decreased expression of NR5A1 mRNA CTD PMID:27122241 NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
JBrowse link
G Nrcam neuronal cell adhesion molecule multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRCAM mRNA CTD PMID:25607892 NCBI chr 6:61,402,813...61,698,536
Ensembl chr 6:61,329,863...61,702,992
JBrowse link
G Nrg1 neuregulin 1 multiple interactions EXP
ISO
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NRG1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NRG1 mRNA
[butylparaben co-treated with NRG1 protein] promotes the reaction [ESR1 protein binds to MYC enhancer]; [NRG1 protein co-treated with butylparaben] results in increased expression of MYC protein; butylparaben promotes the reaction [NRG1 protein results in increased expression of MYC mRNA]; NRG1 protein promotes the reaction [butylparaben results in increased expression of MYC mRNA]
CTD PMID:25607892 PMID:26502914 NCBI chr16:59,250,658...60,303,024
Ensembl chr16:59,250,854...60,296,884
JBrowse link
G Nrxn1 neurexin 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRXN1 mRNA CTD PMID:25607892 NCBI chr 6:3,177,788...4,323,848
Ensembl chr 6:3,177,897...4,322,710
JBrowse link
G Nrxn2 neurexin 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRXN2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NRXN2 mRNA CTD PMID:25607892 NCBI chr 1:203,726,420...203,842,301
Ensembl chr 1:203,735,753...203,842,297
JBrowse link
G Ntrk1 neurotrophic receptor tyrosine kinase 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NTRK1 mRNA CTD PMID:25607892 NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770
JBrowse link
G Ntrk2 neurotrophic receptor tyrosine kinase 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NTRK2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NTRK2 mRNA CTD PMID:25607892 NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
JBrowse link
G Ntrk3 neurotrophic receptor tyrosine kinase 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NTRK3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NTRK3 mRNA CTD PMID:25607892 NCBI chr 1:132,116,472...132,503,849
Ensembl chr 1:132,132,849...132,503,286
JBrowse link
G Nxph3 neurexophilin 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NXPH3 mRNA CTD PMID:25607892 NCBI chr10:80,456,283...80,459,949
Ensembl chr10:80,455,429...80,462,415
JBrowse link
G Otof otoferlin increases expression ISO butylparaben results in increased expression of OTOF mRNA CTD PMID:17121429 NCBI chr 6:25,928,018...26,024,631
Ensembl chr 6:25,928,055...26,024,631
JBrowse link
G Pcdha3 protocadherin alpha 3 increases expression ISO butylparaben results in increased expression of PCDHA3 mRNA CTD PMID:17121429
G Pcdhgc3 protocadherin gamma subfamily C, 3 increases expression ISO butylparaben results in increased expression of PCDHGC3 mRNA CTD PMID:17121429 NCBI chr18:29,633,016...29,667,865 JBrowse link
G Pex14 peroxisomal biogenesis factor 14 increases expression ISO butylparaben results in increased expression of PEX14 mRNA CTD PMID:17121429 NCBI chr 5:159,399,776...159,536,260
Ensembl chr 5:159,399,776...159,536,272
JBrowse link
G Pgr progesterone receptor multiple interactions
increases expression
EXP
ISO
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PGR mRNA; Fulvestrant inhibits the reaction [butylparaben results in increased expression of PGR mRNA]; Fulvestrant inhibits the reaction [butylparaben results in increased expression of PGR protein]
Silver inhibits the reaction [butylparaben results in increased expression of PGR mRNA]
butylparaben results in increased expression of PGR mRNA; butylparaben results in increased expression of PGR protein
CTD PMID:17121429 PMID:19654335 PMID:23524099 PMID:25128701 PMID:25607892 More... NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
JBrowse link
G Pi4ka phosphatidylinositol 4-kinase alpha increases expression ISO butylparaben results in increased expression of PI4KA mRNA CTD PMID:17121429 NCBI chr11:83,609,136...83,726,876
Ensembl chr11:83,609,069...83,724,080
JBrowse link
G Plin1 perilipin 1 increases expression
multiple interactions
ISO butylparaben results in increased expression of PLIN1 mRNA
NR3C1 protein promotes the reaction [butylparaben results in increased expression of PLIN1 mRNA]; PPARG mutant form inhibits the reaction [butylparaben results in increased expression of PLIN1 mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of PLIN1 mRNA]
CTD PMID:22956630 PMID:28527915 NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha increases expression EXP butylparaben results in increased expression of PPARA mRNA CTD PMID:31472229 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases expression
multiple interactions
increases response to substance
increases activity
ISO butylparaben results in increased expression of PPARG mRNA
butylparaben binds to and results in increased activity of PPARG protein
PPARG protein results in increased susceptibility to butylparaben
butylparaben results in increased activity of PPARG protein
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [butylparaben results in increased expression of PPARG mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [butylparaben results in increased expression of PPARG mRNA]; butylparaben promotes the reaction [Dexamethasone results in increased expression of PPARG mRNA]; Mifepristone inhibits the reaction [butylparaben results in increased expression of PPARG mRNA]; PPARG mutant form inhibits the reaction [butylparaben results in increased expression of FABP4 mRNA]; PPARG mutant form inhibits the reaction [butylparaben results in increased expression of PLIN1 mRNA]; PPARG protein inhibits the reaction [butylparaben results in decreased expression of SPP1 mRNA]; PPARG protein promotes the reaction [butylparaben binds to and results in increased activity of PPARG protein]; PPARG protein promotes the reaction [butylparaben results in decreased expression of ALPL mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of CEBPA mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of FABP4 mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of PLIN1 mRNA]
CTD PMID:22956630 PMID:24155963 PMID:27659731 PMID:28527915 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PRKN mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of PRKN mRNA CTD PMID:25607892 NCBI chr 1:48,688,651...49,882,520 JBrowse link
G Prlr prolactin receptor increases expression ISO butylparaben results in increased expression of PRLR mRNA CTD PMID:17121429 NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:59,134,588...59,324,718
JBrowse link
G Pyroxd2 pyridine nucleotide-disulphide oxidoreductase domain 2 decreases expression ISO butylparaben results in decreased expression of PYROXD2 mRNA CTD PMID:17121429 NCBI chr 1:241,523,278...241,549,083
Ensembl chr 1:241,523,377...241,548,761
JBrowse link
G Reln reelin multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of RELN mRNA CTD PMID:25607892 NCBI chr 4:12,736,177...13,162,956
Ensembl chr 4:12,736,130...13,162,211
JBrowse link
G Robo1 roundabout guidance receptor 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ROBO1 mRNA CTD PMID:25607892 NCBI chr11:10,580,863...11,621,672
Ensembl chr11:10,580,908...11,620,203
JBrowse link
G Rps6 ribosomal protein S6 multiple interactions
decreases phosphorylation
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [butylparaben results in decreased phosphorylation of RPS6 protein] CTD PMID:29319206 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation
multiple interactions
ISO butylparaben results in decreased phosphorylation of RPS6KB1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [butylparaben results in decreased phosphorylation of RPS6KB1 protein]; U 0126 inhibits the reaction [butylparaben results in decreased phosphorylation of RPS6KB1 protein]
CTD PMID:29319206 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
JBrowse link
G Runx2 RUNX family transcription factor 2 decreases expression ISO butylparaben results in decreased expression of RUNX2 mRNA CTD PMID:28527915 NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
JBrowse link
G S100g S100 calcium binding protein G multiple interactions
increases expression
EXP Fulvestrant inhibits the reaction [butylparaben results in increased expression of S100G mRNA]; Fulvestrant inhibits the reaction [butylparaben results in increased expression of S100G protein]
butylparaben results in increased expression of S100G mRNA; butylparaben results in increased expression of S100G protein
CTD PMID:19654335 NCBI chr  X:31,705,853...31,708,422
Ensembl chr  X:31,705,866...31,708,433
JBrowse link
G Shank1 SH3 and multiple ankyrin repeat domains 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SHANK1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SHANK1 mRNA CTD PMID:25607892 NCBI chr 1:94,807,879...94,857,356
Ensembl chr 1:94,808,276...94,855,824
JBrowse link
G Shank2 SH3 and multiple ankyrin repeat domains 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SHANK2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SHANK2 mRNA CTD PMID:25607892 NCBI chr 1:199,146,210...199,590,962
Ensembl chr 1:199,169,429...199,589,394
JBrowse link
G Shank3 SH3 and multiple ankyrin repeat domains 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SHANK3 mRNA CTD PMID:25607892 NCBI chr 7:120,568,707...120,630,796
Ensembl chr 7:120,570,402...120,630,374
JBrowse link
G Siah2 siah E3 ubiquitin protein ligase 2 decreases expression ISO butylparaben results in decreased expression of SIAH2 mRNA CTD PMID:17121429 NCBI chr 2:142,913,924...142,931,752
Ensembl chr 2:142,914,003...142,931,950
JBrowse link
G Slc17a7 solute carrier family 17 member 7 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC17A7 mRNA CTD PMID:25607892 NCBI chr 1:95,649,709...95,661,591
Ensembl chr 1:95,649,745...95,661,588
JBrowse link
G Slc1a1 solute carrier family 1 member 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A1 mRNA CTD PMID:25607892 NCBI chr 1:226,549,932...226,631,925
Ensembl chr 1:226,549,842...226,630,402
JBrowse link
G Slc1a2 solute carrier family 1 member 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLC1A2 mRNA CTD PMID:25607892 NCBI chr 3:89,005,129...89,126,498
Ensembl chr 3:89,005,129...89,126,498
JBrowse link
G Slc1a3 solute carrier family 1 member 3 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLC1A3 mRNA CTD PMID:25607892 NCBI chr 2:57,755,495...57,830,605
Ensembl chr 2:57,755,497...57,830,605
JBrowse link
G Slc1a6 solute carrier family 1 member 6 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A6 mRNA CTD PMID:25607892 NCBI chr 7:10,841,836...10,870,424
Ensembl chr 7:10,841,837...10,870,449
JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO butylparaben inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
JBrowse link
G Slit1 slit guidance ligand 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SLIT1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLIT1 mRNA CTD PMID:25607892 NCBI chr 1:240,409,559...240,558,127
Ensembl chr 1:240,409,561...240,558,127
JBrowse link
G Smc1a structural maintenance of chromosomes 1A increases expression ISO butylparaben results in increased expression of SMC1A mRNA CTD PMID:17121429 NCBI chr  X:21,103,323...21,148,053
Ensembl chr  X:21,103,282...21,148,056
JBrowse link
G Sox15 SRY-box transcription factor 15 increases expression ISO butylparaben results in increased expression of SOX15 mRNA CTD PMID:17121429 NCBI chr10:54,373,602...54,376,591
Ensembl chr10:54,372,403...54,376,591
JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions
decreases expression
ISO NR3C1 protein promotes the reaction [butylparaben results in decreased expression of SPP1 mRNA]; PPARG protein inhibits the reaction [butylparaben results in decreased expression of SPP1 mRNA] CTD PMID:28527915 NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
JBrowse link
G Sptbn2 spectrin, beta, non-erythrocytic 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SPTBN2 mRNA CTD PMID:25607892 NCBI chr 1:202,002,970...202,045,343
Ensembl chr 1:202,002,970...202,044,283
JBrowse link
G Star steroidogenic acute regulatory protein decreases expression EXP butylparaben results in decreased expression of STAR mRNA; butylparaben results in decreased expression of STAR protein CTD PMID:18648085 PMID:26888303 NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
JBrowse link
G Stmn2 stathmin 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STMN2 mRNA CTD PMID:25607892 NCBI chr 2:93,204,690...93,252,011
Ensembl chr 2:93,204,692...93,252,011
JBrowse link
G Sts steroid sulfatase multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of STS mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of STS mRNA CTD PMID:25607892 NCBI chr  X:42,225,131...42,233,403
Ensembl chr  X:42,225,372...42,233,402
JBrowse link
G Stx1b syntaxin 1B multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STX1B mRNA CTD PMID:25607892 NCBI chr 1:182,415,544...182,434,385
Ensembl chr 1:182,415,546...182,441,280
JBrowse link
G Stxbp1 syntaxin binding protein 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of STXBP1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STXBP1 mRNA CTD PMID:25607892 NCBI chr 3:16,076,725...16,138,431
Ensembl chr 3:16,076,391...16,138,369
JBrowse link
G Sult1e1 sulfotransferase family 1E member 1 decreases expression EXP butylparaben results in decreased expression of SULT1E1 mRNA; butylparaben results in decreased expression of SULT1E1 protein CTD PMID:26888303 NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275
JBrowse link
G Syngap1 synaptic Ras GTPase activating protein 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SYNGAP1 mRNA CTD PMID:25607892 NCBI chr20:5,026,366...5,056,659
Ensembl chr20:5,026,364...5,056,672
JBrowse link
G Syp synaptophysin multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SYP mRNA CTD PMID:25607892 NCBI chr  X:14,849,444...14,864,553
Ensembl chr  X:14,849,444...14,864,745
JBrowse link
G Syt6 synaptotagmin 6 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SYT6 mRNA CTD PMID:25607892 NCBI chr 2:191,093,009...191,152,283
Ensembl chr 2:191,093,007...191,149,956
JBrowse link
G Tcea3 transcription elongation factor A3 increases expression ISO butylparaben results in increased expression of TCEA3 mRNA CTD PMID:17121429 NCBI chr 5:148,476,941...148,509,452
Ensembl chr 5:148,476,941...148,509,448
JBrowse link
G Tff1 trefoil factor 1 multiple interactions
increases expression
ISO Fulvestrant inhibits the reaction [butylparaben results in increased expression of TFF1 mRNA]; Silver inhibits the reaction [butylparaben results in increased expression of TFF1 mRNA] CTD PMID:16797915 PMID:17121429 PMID:22562034 PMID:23524099 PMID:29074358 NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of TGFB1 mRNA CTD PMID:25607892 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tnfrsf10b TNF receptor superfamily member 10b increases expression ISO butylparaben results in increased expression of TNFRSF10A mRNA CTD PMID:24481588 NCBI chr15:44,839,818...44,867,582 JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B multiple interactions ISO butylparaben promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased secretion of TNFRSF11B protein] CTD PMID:31016361 NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
JBrowse link
G Tnfrsf1a TNF receptor superfamily member 1A increases expression ISO butylparaben results in increased expression of TNFRSF1A mRNA CTD PMID:24481588 NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
JBrowse link
G Tnfrsf21 TNF receptor superfamily member 21 decreases expression ISO butylparaben results in decreased expression of TNFRSF21 mRNA CTD PMID:24481588 NCBI chr 9:17,879,156...17,954,085
Ensembl chr 9:17,879,156...17,954,085
JBrowse link
G Tpo thyroid peroxidase increases expression
increases activity
EXP butylparaben results in increased expression of TPO mRNA
butylparaben results in increased activity of TPO protein
CTD PMID:32798586 NCBI chr 6:46,698,402...46,768,199
Ensembl chr 6:46,698,414...46,768,199
JBrowse link
G Tsc2 TSC complex subunit 2 multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of TSC2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of TSC2 mRNA CTD PMID:25607892 NCBI chr10:13,621,135...13,655,773
Ensembl chr10:13,621,136...13,655,951
JBrowse link
G Tshb thyroid stimulating hormone subunit beta increases expression EXP butylparaben results in increased expression of TSHB protein CTD PMID:32798586 NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
JBrowse link
G Tsnax translin-associated factor X multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of TSNAX mRNA CTD PMID:25607892 NCBI chr19:52,975,848...52,989,886
Ensembl chr19:52,975,659...52,989,878
JBrowse link
G Tspo translocator protein decreases expression EXP butylparaben results in decreased expression of TSPO mRNA CTD PMID:18648085 NCBI chr 7:114,720,188...114,730,450
Ensembl chr 7:114,720,188...114,730,450
JBrowse link
G Ubd ubiquitin D decreases expression ISO butylparaben results in decreased expression of UBD mRNA CTD PMID:17121429 NCBI chr20:1,385,487...1,387,438
Ensembl chr20:1,385,864...1,408,639
JBrowse link
G Unc5a unc-5 netrin receptor A multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of UNC5A mRNA CTD PMID:25607892 NCBI chr17:9,614,841...9,670,558
Ensembl chr17:9,614,838...9,670,526
JBrowse link
G Unc5b unc-5 netrin receptor B multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of UNC5B mRNA CTD PMID:25607892 NCBI chr20:28,697,726...28,764,474
Ensembl chr20:28,697,726...28,764,537
JBrowse link
G Unc5c unc-5 netrin receptor C multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of UNC5C mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of UNC5C mRNA CTD PMID:25607892 NCBI chr 2:230,180,353...230,535,219
Ensembl chr 2:230,180,951...230,535,217
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of VEGFA mRNA CTD PMID:25607892 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
G Vill villin-like increases expression ISO butylparaben results in increased expression of VILL mRNA CTD PMID:17121429 NCBI chr 8:118,776,718...118,794,983
Ensembl chr 8:118,776,742...118,794,983
JBrowse link
G Vldlr very low density lipoprotein receptor multiple interactions EXP [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of VLDLR mRNA CTD PMID:25607892 NCBI chr 1:224,813,539...224,850,400
Ensembl chr 1:224,814,377...224,845,920
JBrowse link
G Wnk4 WNK lysine deficient protein kinase 4 increases expression ISO butylparaben results in increased expression of WNK4 mRNA CTD PMID:17121429 NCBI chr10:86,202,552...86,219,655
Ensembl chr10:86,188,812...86,231,829
JBrowse link
G Zfp397 zinc finger protein 397 increases expression ISO butylparaben results in increased expression of ZNF397 mRNA CTD PMID:17121429 NCBI chr18:15,241,764...15,253,148
Ensembl chr18:15,242,096...15,300,984
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19812
    chemical entity 19812
      atom 19811
        nonmetal atom 19698
          carbon atom 19620
            organic molecular entity 19620
              Butylparaben 243
Path 2
Term Annotations click to browse term
  CHEBI ontology 19812
    subatomic particle 19811
      composite particle 19811
        hadron 19811
          baryon 19811
            nucleon 19811
              atomic nucleus 19811
                atom 19811
                  main group element atom 19708
                    p-block element atom 19708
                      carbon group element atom 19630
                        carbon atom 19620
                          organic molecular entity 19620
                            Butylparaben 243
paths to the root